

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A pharmaceutical composition comprising:

- (a) a carrier portion;
- (b) a targeting portion, wherein said targeting portion comprises a targeting peptide that targets cancerous cells, tumor vasculature or neovasculature; and
- (c) an immune response triggering portion, wherein said immune response triggering portion is galactose- α -1,3-galactose which triggers a complement mediated hyperacute immune response;

wherein neither the carrier portion of (a) nor the targeting portion of (b) is an antibody or antibody fragment.

2. (Original) The pharmaceutical composition of claim 1, wherein said carrier portion is human serum albumin (HSA).

3. (Original) The pharmaceutical composition of claim 1, wherein said targeting peptide comprises asparagine-glycine-arginine (NGR).

4. (Cancelled)

5. (Withdrawn) A method for selectively inducing a complement mediated hyperacute immune response to a target tissue comprising treating said tissue with a pharmaceutical composition comprising a carrier portion, a targeting portion and an immune response triggering portion, wherein said targeting portion binds to cells on said tissue.

6. (Withdrawn) The method of claim 5, wherein said target tissue is the vasculature of a primary or metastatic solid tumor.

7. (Withdrawn) The method of claim 6, wherein said tumor is a lung, colorectal, bladder, prostate, breast, renal, brain, pancreatic, head, neck or an ovarian tumor.

8. (Withdrawn) The method of claim 5, wherein said carrier portion is HSA, said targeting portion is NGR and said triggering portion is gal- α -1,3-gal.

9. (Withdrawn) The method of claim 5, wherein the method of administration of said composition is intravenous.

10. (Previously Presented) A kit comprising, in a suitable container, a pharmaceutical composition comprising

- (a) a carrier portion;
- (b) a targeting portion, wherein said targeting portion comprises a targeting peptide that targets cancerous cells, tumor vasculature or neovasculature; and
- (c) an immune response triggering portion, wherein said immune response triggering portion is galactose- α -1,3-galactose which triggers a complement mediated hyperacute immune response;

wherein neither the carrier portion of (a) nor the targeting portion of (b) is an antibody or antibody fragment.

11. (Original) The kit of claim 10, wherein said targeting portion and carrier portion is not an antibody or antibody fragment.

12. (Original) The kit of claim 10, wherein said targeting portion selectively binds to tumor vasculature.

13. (Original) The kit of claim 10, wherein said targeting portion is a molecule selected from the group consisting of an inhibitor, a ligand, an agonist, an antagonist, and a substrate.

14. (Original) The kit of claim 10, wherein said targeting portion comprises a targeting peptide.

15. (Original) The kit of claim 14, wherein said targeting peptide comprises asparagine-glycine-arginine (NGR).

16. (Original) The kit of claim 10, where said triggering portion triggers a complement mediated hyperacute immune response.

17. (Canceled)

18. (Original) The kit of claim 10, wherein said carrier portion is HSA, said targeting portion is NGR and said triggering portion is galactose- α -1,3-galactose.